Anti-abeta vaccine therapy

EP4654990A1Pending Publication Date: 2025-12-03AC IMMUNE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2024702353
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-26
Filing Date
2024-01-26
Publication Date
2025-12-03

Smart Images

  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000018_0001
    Figure IMGF000018_0001
  • Figure IMGF000030_0001
    Figure IMGF000030_0001
Patent Text Reader

Abstract

A liposomal vaccine composition comprising a !-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of Aβ, a peptide comprising a universal T-cell epitope and an adjuvant comprising monophosphoryl lipid A (MPLA) is used for inducing an anti-Aβ immune response in a human subject without inducing a serious adverse event. The !-amyloid (Aβ)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300-2000 µg. The liposomal vaccine composition is administered intramuscularly or subcutaneously.
Need to check novelty before this filing date? Find Prior Art